GB Sciences, Inc. engages in the biopharmaceutical research and development of cannabis plant into medicines, therapies, and treatments. It intends to identify and develop cannabis-based therapies that target specific diseases or medical conditions. The company was founded on April 4, 2001 and is headquartered in Las Vegas, NV.
Company profile
Ticker
GBLX
Exchange
Website
CEO
John Poss
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Diabetic Treatment Centers of America, Inc., FLAGSTICK VENTURES INC, Growblox Sciences, Inc., Signature Exploration & Production Corp.
SEC CIK
Corporate docs
Subsidiaries
GBS Global Biopharma, Inc. • ECRX, Inc. • The PhAROS Institute, LLC • GB Sciences Texas, LLC ...
GBLX stock data
Latest filings (excl ownership)
10-Q
2024 Q3
Quarterly report
12 Feb 24
10-Q
2024 Q2
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
424B3
Prospectus supplement
10 Oct 23
8-K
Unregistered Sales of Equity Securities
8 Sep 23
10-Q
2023 Q1
Quarterly report
14 Aug 23
D
$1.00 mm in debt / options, sold $75.00 k, 2 investors
2 Aug 23
10-K
2023 FY
Annual report
14 Jul 23
NT 10-K
Notice of late annual filing
30 Jun 23
8-K
Departure of Directors or Certain Officers
14 Apr 23
Latest ownership filings
4
JOHN C POSS
27 Jul 18
3
JOHN C POSS
27 Jul 18
SC 13G/A
GB Sciences Inc
22 Dec 17
SC 13G/A
GB Sciences Inc
15 Nov 17
4
Craig Ellins
7 Aug 17
3
Craig Ellins
16 Jun 17
4
Craig Ellins
16 Jun 17
SC 13D/A
GB Sciences Inc
31 May 17
SC 13D/A
Growblox Sciences, Inc.
8 Feb 17
SC 13D/A
Growblox Sciences, Inc.
18 Nov 16
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 104.53 k | 104.53 k | 104.53 k | 104.53 k | 104.53 k | 104.53 k |
Cash burn (monthly) | (no burn) | 46.10 k | 183.83 k | 344.89 k | 137.51 k | 94.76 k |
Cash used (since last report) | n/a | 339.50 k | 1.35 mm | 2.54 mm | 1.01 mm | 697.82 k |
Cash remaining | n/a | -234.97 k | -1.25 mm | -2.44 mm | -908.08 k | -593.29 k |
Runway (months of cash) | n/a | -5.1 | -6.8 | -7.1 | -6.6 | -6.3 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|